Thu, 20 Sep 2018 08:06:00 +0100
hVIVO's sales pipeline at strongest for years as it bags
Thu, 20 Sep 2018 07:36:00 +0100
Frontier IP takes stake in antibiotics developer spun out from University of Plymouth
Research has shown that epidermicin can be six times more effective than traditional antibiotics in treating infections such as MRSA and Streptococcus
Wed, 19 Sep 2018 15:22:00 +0100
Skinny Tan maker InnovaDerma hails breakthrough Boots deal as it says it is poised for significant growth
Available on Boots.com from next February, the Skinny Tan range will start appearing on the shelves of 1,250 stores nationwide from March
Tue, 18 Sep 2018 17:44:00 +0100
KushCo Holdings reports fiscal 2018 revenue up more than 170%
New distribution centers were launched in the US while an office was opened in Canada
Mon, 17 Sep 2018 13:48:00 +0100
Faron Pharma submits clinical trial application for its precision cancer immunotherapy
It paves the way for a Phase I/II study, called MATINS, that will assess the safety and efficacy of the drug candidate
Mon, 17 Sep 2018 13:23:00 +0100
Faron Pharma: Making sense of the recent news flow
Context is everything when it comes to junior drugs stocks. However, the reaction to failure tends to be binary
Fri, 14 Sep 2018 12:49:00 +0100
ValiRx has raised
Fri, 14 Sep 2018 07:26:00 +0100
AstraZeneca leukaemia drug receives US regulatory green light
In clinical trials, 75% of the people taking the drug responded to it. In 30% of cases, Lumoxiti had a “complete durable” effect
Thu, 13 Sep 2018 11:56:00 +0100
Faron Pharma boss “excited” to begin first in-human trial of Clevegen later this year
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
Wed, 12 Sep 2018 14:12:00 +0100
Faron Pharma says evidence base building around its technology
Clever-1 is a cell surface receptor shown to control a certain form of immunity
Wed, 12 Sep 2018 13:58:00 +0100
ReNeuron will begin clinical trial shortly; upbeat on potential deals
The cell technology group said the first of a group of 110 patients taking part in PICSE III will be enrolled soon
Wed, 12 Sep 2018 10:32:00 +0100
Medica Group reports strong half-year results as NightHawk and Cross Sectional divisions boost revenues
The teleradiology firm reported underlying earnings (EBITDA) growth of 15.1% to
Wed, 12 Sep 2018 07:31:00 +0100
Faron Pharma welcomes latest Clever-1 data
Clever-1 is a cell surface receptor shown to control cell-mediated immunity
Tue, 11 Sep 2018 10:11:00 +0100
Synairgen, Verona Pharma and why DCF analysis doesn't provide the full picture
A valuation model is only as good as the data plugged in (or omitted)
Thu, 06 Sep 2018 12:43:00 +0100
Summit identifies possible new ways to treat hospital-acquired superbugs
Using its Discuva platform, Summit has identified genes which are essential for pathogens like MRSA to survive, information which it will use to try to develop new drug candidates
Thu, 06 Sep 2018 07:10:00 +0100
ValiRx chief says company is at an exciting phase as it updates on two key cancer candidates
Chief executive, Dr Satu Vainikka, said she looked forward to the “successful crystallisation of substantial value for patients and shareholders"
Wed, 05 Sep 2018 15:34:00 +0100
CAR-T therapies: All you wanted to know and were too afraid to ask
Immuno-oncology has become a popular field of research with UK companies at the forefront of the latest innovations
Wed, 05 Sep 2018 10:21:00 +0100
Hutchison ChinaMediTech's colorectal cancer treatment approved in China
Colorectal cancer is the second most common cancer type in China, with about 380,000 new cases per year
Wed, 05 Sep 2018 07:43:00 +0100
Motif Bio: Latest data burnishes the credentials of new antibiotic
iclaprim is being developed to treat serious skin infections
Tue, 04 Sep 2018 11:16:00 +0100
OptiBiotix Health agrees US licensing deal for cholesterol-lowering bacteria
“This is a substantive investment by our US partner which recognises the potential of our strain and the scale of the opportunity in one of the largest and fastest growing markets around the world," said chief executive Stephen O’Hara
Tue, 04 Sep 2018 07:52:00 +0100
Redx Pharma receives regulatory green light to restart cancer trial
RXC004 is one of a new breed of immune-oncology treatments currently in clinical development
Tue, 04 Sep 2018 07:26:00 +0100
Arix Bioscience CEO to transition into new role in preparation for next stage of growth
Joe Anderson’s venture capital background made him an ideal fit for the CEO role during Arix’s early years, but the time has come for a new face to take the firm through its next stage of growth
Mon, 03 Sep 2018 15:01:00 +0100
SkinBioTherapeutics cream successful in stability testing
Demonstrating the extended stability of the cream formulation was a key step to commencing the human study - chief executive, Dr Cath O’Neill
Mon, 03 Sep 2018 13:45:00 +0100
Tissue Regenix makes strong operational and financial progress
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
Mon, 03 Sep 2018 08:50:00 +0100
IXICO to seek shareholders' permission for a capital reorganisation
In common with some other companies, IXICO has decided it has way too many shareholders on the register with negligible shareholdings. It plans to offer them a way to offload those shares without incurring dealing costs.
Fri, 31 Aug 2018 12:15:00 +0100
Midatech Pharma “delighted” with first-in-human data for MTD201 drug
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
Thu, 30 Aug 2018 08:15:00 +0100
AstraZeneca’s new diabetes autoinjector pen approved by European regulators
“Today's approval of Bydureon BCise will enable us to offer an additional treatment option for patients with type-2 diabetes whose blood sugar levels are inadequately controlled by other glucose-lowering medicines together with diet and exercise”
Mon, 27 Aug 2018 11:15:00 +0100
Licensing deals are the life blood for UK drug developers
The act of securing of licensing deals and partnerships is such an important value inflexion point for smaller drug developers it warrants a more detailed write up of its own
Mon, 27 Aug 2018 09:15:00 +0100
Tumour Trace: A revolution in cancer detection
Here we look at an emerging medical technology that has come up with a scientific breakthrough that transforms the way we pick up the tell-tale signs of the killer disease
Sat, 25 Aug 2018 09:42:00 +0100
Artios Pharma fundraiser reveals huge interest in a new area of cancer treatment
The Cambridge-based drug developer recently raised
Thu, 13 Sep 2018 15:51:00 +0100
Faron Pharma to take Clevegen cancer candidate into the clinic this year
Markku Jalkanen, chief executive of (), spoke to Proactive's Andrew Scott following the release of their interim results.
He says he's looking forward to kicking off the first in-human trial of the firm’s Clevegen cancer candidate later this year.
Clevegen is one of a new generation of drugs that helps to weaken a tumour’s ability to suppress the human immune system.
The focus on oncology comes after disappointing Phase III top-line data from their lead drug, Traumakine for the condition called acute respiratory distress.
Wed, 21 Feb 2018 12:14:00 +0000
A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine results in Q2
Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (), caught up with Proactive following their
Wed, 06 Sep 2017 12:54:00 +0100
Faron Pharmaceuticals boss upbeat as Phase III trial enters critical period
Dr Markku Jalkanen, chief executive of Faron Pharmaceuticals Ltd () tells Proactive's Andrew Scott they're entering an exciting period for the company with recruitment for their Phase III trial for its lead drug set for completion later this year.
A positive readout for Traumakine, which is used to treat acute respiratory distress syndrome caused by pneumonia, would pave the way for its launch in Europe and the US.
Clevegen, Faron’s cancer immunotherapy, is set to undergo preclinical toxicity studies.
Tue, 18 Apr 2017 13:22:00 +0100
Faron Pharmaceuticals' Markku Jalkanen 'excited' to be advancing Clevegen
Markku Jalkanen, chief executive of clinical stage biopharma group () tells Proactive he's hugely excited to be teaming up with the University of Birmingham as they look to advance their potential cancer immunotherapy, Clevegen.
Wed, 29 Mar 2017 15:59:00 +0100
'This year will give us the results we've been waiting for', says Faron pharmaceuticals boss
Faron Pharmaceuticals Ltd () CEO Dr Markku Jalkanen caught up with Proactive to run through the company's 2016 results and outlook for the year ahead.
Traumakine, used to treat acute respiratory distress syndrome, is undergoing a phase III clinical trial with results expected in the second half.
Traumakine is now being developed for a second indication, a condition called rupture of abdominal aorta aneurysm.
Thu, 09 Feb 2017 11:36:00 +0000
Faron Pharmaceuticals to build on success of 'extremely exciting' 2016
Dr Markku Jalkanen, chief executive,
Mon, 31 Oct 2016 13:23:00 +0000
Faron Pharmaceuticals boss says patent protection is very significant step
() chief executive Dr Markku Jalkanen says securing patent protection is a very significant step for the company.
“This is the very first ever granted claims to protect intravenous use of interferon-beta,” he highlighted in a Proactive Investors interview.
The drug developer now intends to transpose the patent protections in Finland across some 150 countries covered by international co-operation arrangements, and it will separately file into the US patents office.
“So this was the very initial filing and we are really happy that we got the claims accepted and it is a very significant step for us.”
Wed, 28 Sep 2016 11:01:00 +0100
Faron Pharmaceuticals Oy’s options widen after fund-raising
Demand for shares in ’s () was strong when the company tapped the City last week for
Tue, 06 Sep 2016 15:25:00 +0100
Faron Pharmaceuticals Oy boss pleased with healthier than expected cash balance
() ended the first half of 2016 with more cash than it had anticipated.
Research & development (R&D) expenses more than doubled, but the combination of higher than anticipated income, in the form of both revenue and grant income, and lower operating costs meant the company experienced only a modest cash outflow over the reporting period.
Chief executive Dr Markku Jalkanen told Proactive revenue comprised mostly of a ˆ750,000 signing fee from Pharmbio and a ˆ356,500 pre-payment relating to IFB-beta production.
The group also received ˆ968,000 from the European Union from its FP7 Traumakine grant.
The company had a cash balance of ˆ8.9mln at the end of June, it revealed in its results for the first half of the year.
Wed, 29 Jun 2016 12:46:00 +0100
Faron Pharmaceuticals drug has ‘tremendous potential’ following Korea deal, says CEO
Finland-based clinical stage drug discovery company Faron Pharmaceuticals () says there is “tremendous expansion potential” following the latest licensing deal with a Korean pharmaceuticals firm.
The group’s treatment for Acute Respiratory Distress Syndrome, Traumakine is on track to be the very first pharmacological treatment for this serious condition, explains chief executive Markku Jalkanen.
“The disease is very deadly, death usually occurs in 30-45% of patients,” says Jalkanen. The treatment is already in phase III trials in Europe and licences have been picked up by three companies in Asia, including the deal with Korean firm Pharmbio.
Speaking of the potential licences in its three major areas, including immunotherapy, chronic infection and vaccination, Jalkanen says that “if successful they will last for twenty years from now, so it’s a long term business opportunity for anyone utilising these technologies.”
Tue, 19 Apr 2016 11:03:00 +0100
Faron Pharma chief hopes for global patent protection for Clevegen
Markku Jalkanen, chief executive of
Wed, 03 Feb 2016 09:02:00 +0000
Faron Pharmaceuticals boss talks Traumakine and recent listing on AIM
Finland-based () has a pipeline of products focusing on acute organ traumas, cancer immunotherapy and vascular damage with its most promising product – Traumakine – a late stage product for acute respiratory distress syndrome.
Speaking to Proactive, chief executive Markku Jalkanen said the treatment, currently in Phase III trials in Europe, would be the first non-mechanical treatment for ARDS in the world.
The firm listed on AIM in November raising
view page: 86